Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its antibody-drug conjugate Dato-DXd marketed ...
AstraZeneca and Daiichi Sankyo have claimed approval in the EU ... The green light from the European Commission means that Enhertu (trastuzumab deruxtecan) can now be used for patients whose ...
The green light from the European Medicines Agency is the first ... In December, Astra and Daiichi withdrew an application in the EU for the drug to treat a type of lung cancer after feedback ...
The committee's recommendation was based on data from the TROPION-Breast01 trial, which also supported the US approval of Datroway in January.
European shares end higher as markets bet on more ECB policy easing September 23, 2024 AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not ...
A new European survey sponsored by AstraZeneca (AZ) and Daiichi Sankyo has revealed widespread misconceptions about breast cancer and metastatic cases of the disease. The online questionnaire gathered ...
Revenue growth was fueled by oncology products, particularly ENHERTU ... ENHERTU’s growth to offset Datroway’s shortfall. Daiichi Sankyo’s Q3 FY2024 results reflect strong performance ...
TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1 ...
Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) announced Friday that an expert panel of the EU drug regulator, the European Medicines ... s Committee for Medicinal Products for Human Use (CHMP ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback